Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4205-4209

  Hanna, Nader N ^a   Mauceri, Helena J ^a   Wayne, Jeffery D ^a   Hallahan, Dennis E ^a   Kufe, Donald W ^b   Weichselbaum, Ralph R ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CYTOPATHOGENIC EFFECT; GENE THERAPY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NUCLEOSIDE DEAMINASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030768615     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Weichselbaum, R. R., Beckett, M. A., Vokes, E. E., Brachman, D. G., Haraf, D., Hallahan, D., and Kufe, D. Cellular and molecular mechanisms of radioresistance. Cancer Treat Res., 74: 131-140, 1995.
2. The Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads) + 5-FU, and high dose radiation + 5-FU. Cancer (Phila.), 48: 1705-1710, 1981.
3. The Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med., 312: 1465-1472, 1985.
4. Arcangeli, G., Angelini, F., Arcangeli, G., Tersigni, R., D'Aprile, M., Micheli, A., Veltri, E., Ambrogi, C., Alessandroni, L., Giovinazzo, G., and D'Angelo, L. A pilot study of concomitant protracted venous infusion 5-fluorouracil and hyperfractionated radiotherapy in rectal tumors. Am. J. Clin. Oncol., 18: 369-375, 1995.
5. Moertel, C. G., Childs, D. S., Jr., Reitemeier, R. J., Colby, M. Y., Jr., and Holbrook, M. A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet, 2: 865-867, 1969.
6. O'Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., and Rich, T. A., Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med., 331: 502-507, 1994.
7. Weichselbaum, R. R., Wayne, J. D., Mauceri, H. J., Seung, L. P., Hanna, N. N., Kharbanda, S., Hallahan, D. E., and Kufe, D. W. Ionizing Radiation: A Molecular Switch for Gene Therapy. In: R. E. Sobol and K. J. Scanlon (eds.), The Internet Book of Gene Therapy, pp. 205-210. Stamford, CT: Appleton & Lange, 1995.
8. Hallahan, D. E., Mauceri, H. J., Seung, L. P., Dunphy, E. J., Wayne, J. D., Hanna, N. N., Toledano, A., Hellman, S., Kufe, D. W., and Weichselbaum, R. R. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med., 1: 786-791, 1995.
9. Seung, L. P., Mauceri, H. J., Beckett, M. A., Hallahan, D. E., Hellman, S., and Weichselbaum, R. R. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res., 55: 5561-5565, 1995.
10. Huber, B. E., Richards, C. A., and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 88: 8039-8043, 1991.
11. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J. L., and Klatzmann, D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90: 7024-7028, 1993.
12. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
13. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
14. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 91: 8302-8306, 1994.
15. Hirschowitz, E. A., Ohwada, A., Pascal, W. R., Russi, T. J., and Crystal, R. G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther., 6: 1055-1063, 1995.
16. Ohwada, A., Hirschowitz, E. A., and Crystal, R. G. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum. Gene Ther., 7: 1567-1576, 1996.
17. Li, Z., Shanmugam, N., Katayose, D., Huber, B., Srivastava, S., Cowan, K., and Seth, P. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther., 4: 113-117, 1997.
18. Oldfield, E. H., Ram, Z., Culver, K. W., Blaese, R. M., DeVroom, H. L., and Anderson, W. F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther., 4: 39-69, 1993.
19. Kim, J. H., Kim, S. H., Brown, S. L., and Freytag, S. O. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res., 54: 6053-6056, 1994.
20. Culver, K. W., Van Gilder, J., Link, C. J., Carlstrom, T., Buroker, T., Yuh, W., Koch, K., Schabold, K., Doornbas, S., Wetjen, B., and Michael Blaese, R. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther., 5: 343-379, 1994.
21. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H., and Nagataki, S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res., 55: 3105-3109, 1995.
22. Harris, J. D., Gutierrez, A. A., Hurst, H. C., Sikora, K., and Lemoine, N. R. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther., 1: 170-175, 1994.
23. Deonarain, M. P., Spooner, R. A., and Epenetos, A. A. Genetic delivery of enzymes for cancer therapy. Gene Ther., 2: 235-244, 1995.
24. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res., 54: 1503-1506, 1994.
25. Consalvo, M., Mullen, C. A., Modesti, A., Musiani, P., Allione, A., Cavallo, F., Giovarelli, M., and Forni, G. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol., 154: 5302-5312, 1995.
26. Vile, R. G., Diaz, R. M., Castleden, S., and Chong, H. Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Biochem. Soc. Trans., 25: 717-722, 1997.
27. Weichselbaum, R. R., Dahlberg, W., Beckett, M., Karrison, T., Miller, D., Clark, J., and Ervin, T. J. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc. Natl. Acad. Sci. USA, 83: 2684-2688, 1986.
28. Vokes, E. E., Beckett, M., Karrison, T., and Weichselbaum, R. R. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology, 49: 454-460, 1992.
29. Byfield, J. E. Combined use of drugs and radiation in the treatment of liver metastases. Recent Results Cancer Res., 100: 298-306, 1986.
30. Byfield, J. E., Calabro-Jones, P., Klisak, I., and Kulhanian, F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int. J. Radiat. Oncol. Biol. Phys., 8: 1923-1933, 1982.
31. Byfield, J. E. 5-Fluorouracil radiation sensitization: a brief review. Invest. New Drugs, 7: 111-116, 1989.
32. Smalley, S. R., Kimler, B. F., and Evans, R. G. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 20: 207-211, 1991.
33. Smalley, S. R., Kimler, B. F., Evans, R. G., and Dalziel, W. C. Heterogeneity of 5-fluorouracil radiosensitivity modulation in cultured mammalian cell lines. Int. J. Radiat. Oncol. Biol. Phys., 24: 519-525, 1992.
34. Von Der Masse, H. Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumor. Radiother. Oncol., 7: 47-68, 1986.
35. Bruso, C. E., Shewach, D. S., and Lawrence, T. S. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int. J. Radiat. Oncol. Biol. Phys., 19: 1411-1417, 1990.
36. Windholz, M. (ed.). The Merck Index, Vol. 9, p. 534. Rahway, NJ: Merck and Co., Inc., 1976.
37. Wallace, P. M., MacMaster, J. F., Smith, V. F., Kerr, D. E., Senter, P. D., and Cosand, W. L. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res., 54: 2719-2723, 1994.
38. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55: 4808-4812, 1995.
39. Domin, B. A., Mahony, W. B., and Zimmerman, T. P. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol., 46: 503-510, 1993.
40. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.
41. Vile, R. G., and Hart, I. R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res., 53: 3860-3864, 1993.
42. Ram, Z., Wallbridge, S., Shawker, T., Culver, K. W., Blaese, R. M., and Oldfield, E. H. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg., 81: 256-260, 1994.
43. Takamiya, Y., Short, M. P., Ezzeddine, Z. D., Moolten, F. L., Breakefield, X. O., and Martuza, R. L. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res., 33: 493-503, 1992.
44. Manome, Y., Abe, M., Hagen, M. F., Fine, H. A., and Kufe, D. W. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res 54: 5408-5413, 1994.
45. Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther., 4: 725-731, 1993.
46. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
47. Colombo, B. M., Benedetti, S., Ottolenghi, S., Mora, M., Pollo, B., Poli, G., and Finocchiaro, G. The. "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther., 6: 763-772, 1995.
48. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835, 1996.
49. Ishii-Morita, H., Agbaria, R., Mullen, C. A., Hirano, H., Koeplin, D. A., Ram, Z., Oldfield, E. H., Johns, D. G., and Blaese, R. M. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther., 4: 244-251, 1997.
50. Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. In vivo analysis of the "bystander effect": a cytokine cascade. Exp. Hematol., 24: 829-838, 1996.
51. Gagandeep, S., Brew, R., Green, B., Christmas, S. E., Klatzmann, D., Poston, G. J., and Kinsella, A. R. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect." Cancer Gene Ther., 3: 83-88, 1996.
52. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res., 54: 6228-6234, 1994.
53. Vile, R. G., Castleden, S., Marshall, J., Camplejohn, R., Upton, C., and Chong, H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer, 71: 267-274, 1997.
54. Khil, M. S., Kim, J. H., Mullen, C. A., Kim, S. H., and Freytag, S. O. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin. Cancer Res., 2: 53-57, 1996.
55. Kim, J. H., Kim, S. H., Kolozsvary, A., Brown, S. L., Kim, O. B., and Freytag, S. O. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int. J. Radiat. Oncol. Biol. Phys., 33: 861-868, 1995.
56. Kim, S. H., Kim, J. H., Kolozsvary, A., Brown, S. L., and Freytag, S. O. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. J. Neuro-Oncol., 33: 189-194, 1997.
57. Rogulski, K. R., Kim, J. H., Kim, S. H., and Freytag, S. O. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther., 8: 73-85, 1997.
58. Ashe, W. D., Jr., and Van Reken, D. E. 5-Fluorocytosine: a brief review. Clin. Pediatr. (Phila.), 16: 364-366, 1977.
59. Scholer, H. J., Fluorocytosine, In: D. C. E. Spellar (ed.), Antifungal Chemotherapy, pp. 36-106. Chichester, United Kingdom: John Wiley, 1980.